Open Label, Single Arm, Phase II Study Using R-COMP in Elderly Patients With Aggressive NHL.

Exclusion Criteria

• •Clinical stage I non-bulky, or CS IIA with less than three sites of disease involved (patients with stage IIB are eligible, regardless of the number of sites involved);
• •Tumour involvement of CNS;
• •Indolent lymphoma transformed in more aggressive histological type, even if never previously treated;
• •Mantle Cell Lymphoma, Peripheral T cell Lymphoma and their variants;
• •Aggressive non-Hodgkin's lymphoma in transplanted patient;
• •Clinically significant secondary cardiovascular disease, e.g. uncontrolled hypertension, (resting diastolic blood pressure \>115 mmHg), uncontrolled multifocal cardiac arrhythmias, symptomatic angina pectoris or congestive cardiac failure NYHA class III-IV;
• •Evidence of any severe active acute or chronic infection;
• •Concurrent malignancy or history of other malignancy, except basal cell carcinoma of the skin (BCC) and in-situ cervical carcinoma (CIN) / Myelodysplastic syndrome;
• •HbsAg, HIV-positive, or HCV-RNA-positive patients;
• •Inability to comply with study procedures;
• •Prior CNS lymphoma;
• •Prior radiation to non-CNS lymphoma mass(es) as a treatment for lymphomas;
• •History of allergic reaction to anthracyclines, eggs, and egg products or known sensitivities, or history of unusual reaction, to other components of, or treatments similar to, the investigational treatment regimen;
• •Presence of other medication that may interfere with study treatment or the action of the investigational product or confuse the assessment of study results
• •Pregnant women or nursing mothers;
• •Participation in an investigational drug study within 4 weeks prior to study entry.